GlassScriptPhysician profile
Barbara J Lynch
NPI 1902225881
$9,945.49
in general payments reported to CMS, 2019-2025
33 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,672 · 2022: $2,348 · 2023: $1,186 · 2024: $2,605 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,925.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,787.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,706.69 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $819.36 | 2021-2024 | Trelegy Ellipta, Arexvy, Bexsero |
| Novo Nordisk INC | $722.52 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $696.18 | 2021-2025 | Jardiance, Emgality, Zepbound |
| Janssen Pharmaceuticals, INC | $672.70 | 2021-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.41 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.97 | 2022-2024 | Xifaxan |
| Amarin Pharma, INC. | $335.22 | 2021-2022 | |
| Exact Sciences Corporation | $259.04 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $236.60 | 2021-2025 | |
| Astellas Pharma US INC | $176.68 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $135.33 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $130.70 | 2024 | Ingrezza |
| Nestle Healthcare Nutrition INC. | $124.98 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $107.67 | 2021 | |
| Ironwood Pharmaceuticals, INC | $104.66 | 2022-2024 | Linzess |
| Scpharmaceuticals INC. | $99.45 | 2025 | |
| Novartis Pharmaceuticals Corporation | $98.99 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $88.52 | 2023-2025 | Gemtesa |
| Genzyme Corporation | $84.83 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $82.66 | 2021-2022 | |
| Amgen INC. | $70.34 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $50.45 | 2021 | |
| Lundbeck LLC | $50.42 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $50.23 | 2022-2023 | |
| Dexcom, INC. | $47.54 | 2021-2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.34 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $46.76 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $46.57 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $33.34 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $25.07 | 2021 | |
| Aimmune Therapeutics, INC. | $19.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.